跳至主要内容
临床试验/NL-OMON29359
NL-OMON29359招募中不适用

Randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects

Acesion Pharma ApSOle Maaløes Vej 3DK-2200 Copenhagen NDenmark0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
48

研究概览

简要总结

To be published

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Signed informed consent prior to any study-mandated procedure
  • 2. Healthy male subjects, 18 to 45 years of age, inclusive.

排除标准

  • 1. Evidence of any active or chronic disease or condition that could interfere with, or for which
  • the treatment might interfere with, the conduct of the study, or that would pose an
  • unacceptable risk to the subject in the opinion of the investigator (following a detailed
  • medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse
  • rate, body temperature), 12-lead electrocardiogram (ECG), and clinical laboratory
  • parameters (haematology, blood chemistry, and urinalysis)). Minor deviations of laboratory
  • values from the normal range may be accepted, if judged by the Investigator or medically
  • qualified designee as not clinically significant.

研究者

发起方
Acesion Pharma ApSOle Maaløes Vej 3DK-2200 Copenhagen NDenmark

相似试验